Le Lézard
Classified in: Health
Subject: PER

Retired Brigadier General Jack Hammond Joins the BioDirection Military Advisory Board


BOSTON, Jan. 17, 2018 /PRNewswire/ -- BioDirection, a privately held medical device company developing novel and rapid point-of-care products for the diagnosis and management of concussions and other acquired traumatic brain injuries, today announced the appointment of retired Brigadier General Jack Hammond to the company's Military Advisory Board.

"As co-chairman of our Military Advisory Board, I am excited about working alongside General Hammond to develop and implement strategies for broadening our relationship with the Department of Defense and the U. S. Military," said Stephen Brackett, director of BioDirection. "General Hammond has a passion for the safety and well-being of our military developed over his distinguished career in the U.S. Army. We are indeed fortunate to have a man of his experience on our team."

During his distinguished 30-year military career in the U.S. Army, General Hammond commanded troops at the platoon, troop, battalion, and brigade level both at home and abroad, becoming the first Massachusetts officer to achieve the rank of general officer in a combat theater since World War II. Currently, he is the Executive Director of Home Base, a Red Sox Foundation and Massachusetts General Hospital Program that is dedicated to healing the invisible wounds of war affecting service members, veterans, and their families including post traumatic stress (PTS) and traumatic brain injury (TBI). The Boston-based organization provides a unique, intensive clinical care program, fitness and wellness-based programs, and education and research.    

"I have worked closely with Steve Brackett through Home Base, and as a result have observed the development of BioDirection over the last few years," said General Hammond. "The time is right for the company to aggressively pursue military applications for its point-of-care Tbittm System, which is well-suited for use in both military training and deployment situations."

After a brief deployment to Afghanistan in 2002, General Hammond deployed to Iraq in 2003 with the invasion force and simultaneously commanded two battalions; Task Force Patriot in Balad performing stability and security operations, and Task Force Enforcer in Fallujah conducting counter-insurgent operations. In Kabul, Afghanistan from 2011-2012, General Hammond commanded Task Force Yankee as the senior U.S. commander for Kabul Province. He was responsible for a multi-national security force of 3,000 personnel, providing security and support for 11 U.S. installations and 10,000 coalition members conducting counterinsurgency operations, humanitarian assistance, and area support missions.

General Hammond is the recipient of numerous military awards including the Distinguished Service Medal, the Legion of Merit with Oak Leaf Cluster, Bronze Star Medal, Army Commendation Medal for Valor with Oak Leaf Cluster, French Medal of National Defense, and Bulgarian Medal of Mission Support. A native of Reading, Massachusetts, he holds a bachelor of science from the University of Massachusetts, a master's degree in healthcare marketing from Boston University, and was a national security fellow at Harvard University.

About BioDirection, Inc.

BioDirection is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company's lead product, the Tbittm System, delivers biologically-based results shown to accurately confirm a TBI/concussion. BioDirection's platform system utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics. To learn more about BioDirection, visit http://www.biodirection.com.

Contact:


Adam Daley

Eric Goorno, President & CEO

Berry & Company Public Relations

BioDirection, Inc.

Tel: +1 (212) 253-8881

Tel: +1 (508) 308-8592

Email: [email protected]

Email: [email protected]

 

SOURCE BioDirection, Inc.


These press releases may also interest you

at 10:10
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical...

at 10:10
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation...

at 10:07
The American Association of Critical-Care Nurses (AACN) has published "AACN Standards for Appropriate Staffing in Adult Critical Care," the specialty's first, action-oriented staffing standards. Appropriate staffing has long been one of the "AACN...

at 10:05
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered...

at 10:05
Nuvation Bio Inc. , a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I...

at 10:05
AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held...



News published on and distributed by: